Skip to content

SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement

SNIPE:SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01482325
Acronym
SNIPE
Enrollment
31
Registered
2011-11-30
Start date
2011-11-30
Completion date
2013-12-31
Last updated
2016-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure (Low, Normal, High)

Brief summary

The primary objective of this study is to show that the noninvasive blood pressure software algorithm meets engineering requirements.

Interventions

DEVICEBlood pressure monitoring with GE Healthcare DASH2500 Patient Monitor

10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor

Sponsors

GE Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Ability to provide written informed consent or have a legally authorized representative including a parent or guardian provide written informed consent * Ability of a minor subject ages 7 to 18 to provide written assent * Ability to have multiple noninvasive blood pressures taken at one sitting * Ability to apply three lead ECG, if needed for investigation * Ability to detect the natural presence of an irregular pulse, for irregular pulse studies

Exclusion criteria

* Any subject who cannot tolerate multiple blood pressure measurements * Any subject who cannot undergo 3-lead ECG, if needed * Any subject deemed unstable by the principal investigator * Any subject for whom precautions are necessary because of communicable disease * Any subject that has a known disease or condition compromises musculoskeletal integrity * Any subject that has a known disease or condition that contraindicates use of an NIBP cuff and ECG patches on the skin.

Design outcomes

Primary

MeasureTime frameDescription
Data Collection for Engineering DevelopmentAfter each iteration of software developmentThis was a data collection for engineering development to demonstrate SuperSTAT 2.0 NIBP software algorithm meets the engineering specifications. Engineers reviewed data produced by each blood pressure determination to work on new software algorithm in development. This was not conducted as program was terminated prematurely. Software iterations are not pre-defined.

Countries

United States

Participant flow

Participants by arm

ArmCount
Subjects Requiring Blood Pressure Monitoring
Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor: 10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
31
Total31

Baseline characteristics

CharacteristicSubjects Requiring Blood Pressure Monitoring
Age, Continuous48.49 years
STANDARD_DEVIATION 32.74
Sex: Female, Male
Female
18 Participants
Sex: Female, Male
Male
13 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 31
serious
Total, serious adverse events
0 / 31

Outcome results

Primary

Data Collection for Engineering Development

This was a data collection for engineering development to demonstrate SuperSTAT 2.0 NIBP software algorithm meets the engineering specifications. Engineers reviewed data produced by each blood pressure determination to work on new software algorithm in development. This was not conducted as program was terminated prematurely. Software iterations are not pre-defined.

Time frame: After each iteration of software development

Population: Subject analysis was not performed because study was prematurely terminated. Work on the project ceased when it was terminated.The study was intended to have the engineers review data produced by each blood pressure determination to work on new software algorithm in development. This was not and will not be conducted.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026